Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.5K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing acid stability of phycocyanin via non-covalent interactions with gelatin matrices of different Bloom values.

Food chemistry·2026
Same author

A multi-objective optimization framework for planning electric vehicle charging infrastructure incorporating traffic demand, cost, and equity considerations.

Scientific reports·2026
Same author

Depression and risk of incident heart diseases among older adults at CKM stages 0-3: evidence from the China Health and Retirement Longitudinal Study.

Annals of medicine·2026
Same author

Machine Learning Algorithms Enabled Visual On-Site Intelligent Sensing of Bioactive Components by Histidine-Functionalized Nanozyme Sensor Array.

ACS sensors·2026
Same author

Phase measurement and compensation method for a waveguide beam based on an on-chip 90° optical hybrid mixer.

Optics express·2026
Same author

Correction to: Associations of sleep, lifestyle, and physiological markers with healthspan termination: a prospective cohort analysis.

Sleep & breathing = Schlaf & Atmung·2026

Related Experiment Video

Updated: Oct 5, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.5K

Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling

Wenjing Xiong1, Wenzhuo He1,2, Tiantian Wang1

  • 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|January 22, 2022
PubMed
Summary

Loss of Smad4 in pancreatic cancer cells surprisingly boosts anti-tumor immunity. Smad4 deficiency enhances tumor immunogenicity via DNA damage and interferon signaling, activating CD8+ T cells to control cancer growth.

Keywords:
IFN-I signalingSMAD4STINGantitumor immunitypancreatic cancer

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

963
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

Related Experiment Videos

Last Updated: Oct 5, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.5K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

963
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Smad4 is crucial for transforming growth factor-β signaling and is altered in 20% of pancreatic ductal adenocarcinoma (PDAC).
  • The impact of Smad4 loss on PDAC immunogenicity and the tumor immune microenvironment remains largely unknown.

Purpose of the Study:

  • To investigate the role of Smad4 in regulating PDAC immunogenicity and tumor growth.
  • To elucidate the underlying mechanisms by which Smad4 deficiency affects the tumor immune microenvironment.

Main Methods:

  • Utilized Smad4-deficient and wild-type PDAC cell lines in immunocompetent and immunodeficient mouse models.
  • Assessed tumor growth, immune cell infiltration (CD8+ T cells, cDC1s), DNA damage, and type I interferon signaling.
  • Employed gene deletion strategies (Sting, Ifnar1, cDC1 deficiency) to dissect the mechanism.

Main Results:

  • Smad4 deficiency inhibited in vivo PDAC tumor growth in immunocompetent mice, but not in immunodeficient or CD8+ T cell-depleted mice.
  • Smad4 loss increased tumor immunogenicity by inducing DNA damage and activating STING-mediated type I interferon signaling.
  • This pathway led to enhanced activation of type 1 conventional dendritic cells (cDC1s) and CD8+ T cells, mediating tumor control.
  • Tumor growth inhibition was reversed upon Sting, Ifnar1, or cDC1 deficiency, confirming the mechanism.

Conclusions:

  • Smad4 loss unexpectedly suppresses PDAC tumor growth by enhancing immunogenicity through intrinsic DNA damage and STING-dependent type I interferon signaling.
  • This pathway activates cDC1s and CD8+ T cells, highlighting a novel mechanism of tumor immune surveillance in PDAC.